BURLINGTON, Mass. , May 30, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]

Type C Meeting to solidify re-filing plans for FUROSCIX® scheduled with the U.S. Food and Drug Administration ( FDA ) for June 2019 Resubmission of FURSOCIX New Drug Application (NDA) with the FDA in 2020 Balance sheet remains strong with over $83 million in cash BURLINGTON, Mass.[…]

Signed development agreement with West Pharmaceutical Services for next-generation FUROSCIX ® On-Body Infusor Resubmission of FURSOCIX with the U.S. Food and Drug Administration ( FDA ) by year-end 2020 Balance sheet remains strong with over $89 million in cash BURLINGTON, Mass.[…]

BURLINGTON, Mass. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today[…]

Advancing FUROSCIX ® with the SmartDose ® Drug Delivery System Forecast 2018 year-end cash of $82 - $87 million and 2019 expenditures of  $8 - $10 million per quarter BURLINGTON, Mass. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on[…]